Skip to main content
Evidence Snapshot

Cathepsin L2

CHEMBL3272 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3272
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cathepsin L2 as ChEMBL target CHEMBL3272, mapped to UniProt O60911. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cathepsin L2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3272
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O60911
Cathepsin L2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cathepsin L2 matters

As of 2026-09-13

Cathepsin L2 is reviewed as Cathepsin L2 (UniProt O60911); the current evidence base includes 3 approved drugs, 250 compounds, and 40 assays, with lead potency reaching pChEMBL 10.2.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 250 compounds, and 40 assays for this target. The dominant activity type is IC50. CHEMBL203665 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL203665 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
3 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cathepsin L2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O60911, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

250
Total Compounds
40
Total Assays
3
Approved Drugs
IC50: 187.0, KI: 39.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL203665
 10.2 Ki Clinical
No preferred name
CHEMBL286364
 8.7 Ki —
No preferred name
CHEMBL554065
 8.7 IC50 —
No preferred name
CHEMBL562844
 8.5 IC50 —
No preferred name
CHEMBL549378
 8.2 IC50 —

Approved Drugs

Structure Compound First Approval
BOCEPREVIR
CHEMBL218394
 2011
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3272